Director Thomas Frank E buys 5,000 shares of LRMR at $5.00; stock up 47.7% in 30 days, but company unprofitable with -$47.7M net income.
Thomas Frank E increased his stake in Larimar Therapeutics by 250.0% to 7,000 shares via a $25,000 open-market purchase at $5.00 on 2026-02-27. The stock is currently trading at $5.23, up 47.7% over the past 30 days and 67.6% over 90 days, but this recent price strength does not align with the company's fundamentals: Larimar reported zero revenue in its latest quarter and a net loss of -$47.7M for the most recent full fiscal year. The insider's prior buy at this same ticker on 2024-02-14 was poorly timed, with the stock declining 28.4% over the subsequent 90 days, signaling a pattern of unfavorable purchase timing. Additionally, a cluster of 3 other insiders also purchased shares within the past 14 days, which warrants scrutiny given the widening gap between current valuations and the underlying unprofitable, revenue-less business.